US FDA grants TPX-0022 Orphan Drug Designation for the treatment of gastric cancer

TPX-022 is a potent inhibitor of the MET tyrosine kinase. Initial data from an ongoing Phase 1 trial (SHIELD-1) showed it has been generally well-tolerated and demonstrated clinical activity in patients with MET-amplified gastric cancer.

Source:

Biospace Inc.